Melior Discovery in the news

< Back to main News page

Melior Discovery Enters New Pharmaceutical Collaboration

Melior to Apply Its Unique theraTRACE® Discovery Platform to Identify
Potential New Indications for Multiple Drug Compounds

EXTON, PA, August 2, 2007 – Melior Discovery, Inc. today announced that it has signed an agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) to apply Melior’s theraTRACESM indications discovery platform to identify possible new indications for multiple J&JPRD drug candidates. Financial terms
were not disclosed.

Melior’s theraTRACE platform is a comprehensive, multiplexed set of integrated in vivo models designed to systematically and rapidly identify previously unknown applications for pharmaceutical compounds. It can be applied to discovery, development stage and marketed agents and has already identified novel indications for a number of
development stage drugs.

“This agreement presents a significant opportunity for Melior to deliver value through the application of our unique in vivo testing platform to a range of pre-clinical and development stage compounds,” said Andrew Reaume, Ph.D., President and CEO of Melior. “Our theraTRACE indications discovery platform is already proving its value in our existing collaborations with Merck and Pfizer, as well as in screening for our own drug development efforts. We are delighted to be working with J&JPRD, and we look forward to a productive collaboration.”

Melior’s theraTRACE platform is designed to systematically test the potential efficacy of compounds across a large number of disease models rapidly and efficiently, using the same high quality in vivo models developed by leading pharmaceutical researchers to determine whether a drug candidate demonstrates sufficient efficacy to merit advancement into clinical development. Melior’s proprietary multiplexed approach integrates multiple in vivo models and reduces the time, amount of test compound and number of test subjects needed, while also reducing the number of false positive results. As a result, Melior’s platform provides major improvements in efficiency and effectiveness and a reduction in the overall cost of the new indications discovery effort.

Melior Discovery Overview
Melior Discovery is leading the transformation of pharmaceutical drug repositioning with its unique theraTRACE® platform of multiplexed in vivo models. The Company is building a pipeline of drug candidates by identifying “privileged” compounds that have been discontinued by other companies and repositioning these molecules in new high potential therapeutic areas. Melior is fortunate to be working exclusively with Dr. Chris Lipinski who assists the Company in identifying ideal repositioning candidates. In addition, Melior offers pharmaceutical and biotechnology companies an opportunity to expand their development pipelines by accessing the theraTRACE® platform.

Melior Discovery is located in Exton, PA. For more information contact:
Andrew Reaume, Ph.D MBA
President and CEO
Melior Discovery
860 Springdale Drive
Exton, PA 19341
(+1) 610-280-0633 ext 239
e-mail: areaume@meliordiscovery.com

View the Archive

Back to top of page